| 1. |
陈万青, 郑荣寿, 曾红梅, 等. 2011 年中国恶性肿瘤发病和死亡分析. 中国肿瘤, 2015, 24(1): 1-10.
|
| 2. |
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.
|
| 3. |
Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun, 2004, 319(1): 1-11.
|
| 4. |
Roepstorff K, Grovdal L, Grandal M, et al. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol, 2008, 129(5): 563-578.
|
| 5. |
Cho HS, Mason K, Ramyar KX, et al. Structure of the extra-cellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 2003, 421: 756-760.
|
| 6. |
Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J, 1997, 16 (7): 1647-1655.
|
| 7. |
Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA, 2003, 100(15): 8933-8938.
|
| 8. |
Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res, 2006, 12 (21): 6326-6330.
|
| 9. |
Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res, 2003, 284 (1): 99-110.
|
| 10. |
Tominaga N, Gotoda T, Hara M, et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer, Gastric Cancer, 2016, 19(2): 553-560.
|
| 11. |
Watson S, Validire P, Cervera P, et al. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann Oncol, 2013, 24(12): 3035-3039.
|
| 12. |
Huang S, Ng KF, Lee SE, et al. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance, Gastric Cancer, 2016, 19(1), 176-182.
|
| 13. |
Wang T, Hsieh ET, Henry P, et al. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol, 2014, 45(5): 970-975.
|
| 14. |
Ge XW, Wang HX, Zeng HY, et al. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks. Hum Pathol, 2015, 46(6): 850-857.
|
| 15. |
Gumusay O, Benekli M, Ekinci O, et al. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. Jpn J Clin Oncol, 2015, 45(5): 416-421.
|
| 16. |
Fusco N, Rocco EG, Del Conte C, et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol, 2013, 26(6): 816-824.
|
| 17. |
Kochi M, Fujii M, Masuda S, et al. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol, 2013, 8: 191.
|
| 18. |
Ock CY, Lee KW, Kim JW, et al. Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer. Clin Cancer Res, 2015, 21(11): 2520-2529.
|
| 19. |
Gomez-Martin C, Carlos Plaza J, Pazo-Cid RA, et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol, 2013, 31(35): 4445-4452.
|
| 20. |
Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer, 2014, 17(1): 34-42.
|
| 21. |
Cappellesso R, Fassan M, Hanspeter EA, et al. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. Hum Pathol, 2015, 46(5): 665-672.
|
| 22. |
Nagaraja V, Eslick GD. HER2 expression in gastric and oesophageal cancer: a meta-analytic review. J Gastrointest Oncol, 2015, 6(2): 143-154.
|
| 23. |
Huang D, Lu N, Fan QH, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS One, 2013, 8(11): e80290.
|
| 24. |
Genevieve M, Benoit T, Marie-Pierre C, et al. Assessment of HER2 status from an epidemiology study in tumor tissue samples of gastric and gastro-esophageal junction cancer: results from the french cohort of the HER-EAGLE study. 2013 Gastrointestinal Cancers Symposium, 2013, 31: 26.
|
| 25. |
Lourdes G, Angel C, Garcia-Caballero T, et al. Assessment of HER2 status from an epidemiology study in tumor tissue samples of gastric and gastro-esophageal junction cancer: Spanish results of the HER-EAGLE study. 2012 ASCO Annual Meeting, 2012, 30: 4089.
|
| 26. |
Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol, 2011, 18(10): 2833-2840.
|
| 27. |
Yan SY, Hu Y, Fan JG, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol, 2011, 17(11): 1501-1506.
|
| 28. |
Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer: a systematic analysis of data from the literature. J Cancer, 2012, 3: 137-144.
|
| 29. |
Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes: a systematic review. Int J Cancer, 2012, 130(12): 2845-2856.
|
| 30. |
Qiu M, Zhou Y, Zhang X, et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer, 2014, 14: 823.
|
| 31. |
Ryu MH, Yoo C, Kim JG, et al. Multicenter phase Ⅱ study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer, 2015, 51(4): 482-488.
|
| 32. |
Kurokawa Y, Sugimoto N, Miwa H, et al. Phase Ⅱ study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014, 110(5): 1163-1168.
|
| 33. |
Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the Second-Line treatment of HER2-Amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase Ⅲ study. J Clin Oncol, 2014, 32(19): 2039-2049.
|
| 34. |
Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial. 2013 ASCO Annual Meeting, 2013, 31: LBA4001.
|
| 35. |
Kang YK, Rha SY, Tassone P, et al. A phase Ⅱa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer, 2014, 111(4): 660-666.
|
| 36. |
Hoffmann-La R. A study of pertuzumab in combination with trastuzumab and chemotherapy in participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastroesophageal junction or gastric cancer. (2017-05-10)[2017-05-31]. https://clinicaltrials.gov/ct2/show/NCT01774786.
|
| 37. |
Hoffmann-La R. A study of trastuzumab emtansine versus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. (2017-05-05)[2017-05-31]. https://clinicaltrials.gov/ct2/show/NCT01641939.
|
| 38. |
National Comprehensive Cancer Networks (NCCN), Clinical Practice Guidelines in Oncology(NCCN Guidelines), Colon Cancer. Version 2. (2017-03-13)[2017-06-01]. https://www.nccn. org/professionals/physician_gls/pdf/colon.pdf.
|
| 39. |
Zhang XL, Park JS, Park KH, et al. PTEN deficiency as a predictive biomarker of resistance to HER2-Targeted therapy in advanced gastric cancer. Oncology, 2015, 88(2): 76-85.
|
| 40. |
Eto K, Iwatsuki M, Watanabe M, et al. The MicroRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol, 2014, 21(1): 343-350.
|
| 41. |
Zhang Z, Wang J, Ji D, et al. Functional genetic approach identifies Met, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clin Cancer Res, 2014, 20(17): 4559-4573.
|
| 42. |
Chen CT, Kim H, Liska D, et al. Met activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther, 2012, 11(3): 660-669.
|
| 43. |
Hong YS, Kim J, Pectasides E, et al. Src mutation induces acquired lapatinib resistance in ERBB2-Amplified human gastroesophageal adenocarcinoma models. PLoS One, 2014, 9(10): e109440.
|
